CRISPR in the clinic


CRISPR-Cas9 is a genetic tool that can perform molecular surgery on the DNA of a cell. Fundamentally altering the code of life allows scientists to insert and remove genes.

For the first time in a milestone study, CRISPR-Cas9 has been implemented in a clinical setting to alleviate blindness in an untreatable genetic condition known as Leber’s congenital amaurosis.

A single participant with Leber’s congenital amaurosis 10 (LCA10), has been administration CRISPR-Cas9 through injection into the eye near photo-receptor cells (which detect light and color). If successful it may reverse the disease by removing a single mutation in the DNA - allowing sight.

This form of treatment is considered safe since CRISPR-Cas9 stays locally in the eye, and therefore should not travel to other sites of the body.

The estimated time-frame is a month before vision is restored. Success of this trial may result in 18 more patients commencing with treatment in the next trial phase.

Mark Pennesi from Oregon Health & Science University in Portland said to Nature - 'This is one of the few diseases where we think you could actually get an improvement in vision'.

This is a historical moment for genetic editing and life on earth. If insertion of CRISPR-Cas9 into the body proves successful, the gene editing tool will be considered to harness unparalleled potential. Paving the way to address the estimated 1 in 2000 world-wide suffering from single gene retinal inherited mutations.






Comments

Popular posts from this blog

Does the damage from sun exposure outweigh the benefit of getting vitamin D?

What is the 'Good Genes Hypothesis' and is it true?

Mitochondrial Membrane Potential